ScinoPharm, Coland Holdings To Co-Develop Generic Oncologic Drugs
ScinoPharm Taiwan Ltd. and Coland Holdings Ltd. announced this week a strategic alliance to develop a series of generic oncological drugs for Mainland China.
AsianScientist (May 13, 2013) – ScinoPharm Taiwan Ltd. and Coland Holdings Ltd. announced this week a strategic alliance to develop a series of generic oncological drugs for Mainland China.
Under the strategic alliance agreement, ScinoPharm will provide the active pharmaceutical ingredients (APIs), a third party company will be commissioned to develop, formulate and register oncological pharmaceutical products, and then Coland and ScinoPharm will be co-responsible for the marketing and sales efforts in the Chinese market.
Several APIs from ScinoPharm have been initially selected for development and future sales as injectable formulation products. These products are estimated to reach the market in 2017 at the earliest.
The currently selected and targeted anti-cancer products are mostly mainstream pharmaceuticals with large demand and high competitive barriers in the Chinese market, including treatments for lung, breast, and ovarian cancers, as well as MDS and pancreatic cancer. The market value within China for these products came to over 5 billion RMB (US$805 million) last year, demonstrating the immense future market potential resulting from this alliance.
“ScinoPharm is elated to form a strategic alliance with Coland. Resources from both parties will be combined to establish a robust collaboration for assertive development of products for the local anti-cancer medication market in China. This cooperation also marks ScinoPharm’s first move into Chinese market since launching our “Double A” strategy, combining unique APIs with Abbreviated New Drug Applications (ANDAs),” said Dr. Jo Shen, President and CEO of ScinoPharm.
Source: ScinoPharm Taiwan, Ltd.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.